Brucella ceti cDNA and Antigen

Brucella ceti is a species of bacteria in the genus Brucella that is found primarily in marine mammals, particularly cetaceans (whales, dolphins, and porpoises). It is the causative agent of cetacean brucellosis, a contagious and often fatal bacterial disease of these animals. The bacteria is spread through contact with infected animals or their secretions, including milk and other body fluids. Common symptoms of the disease in infected animals include fever, anorexia, lethargy, abortions, and infertility. Treatment of the disease is possible, but long-term management of infected animals is often required to minimize the risk of transmission to other animals.

Brucella ceti can cause brucellosis in marine mammals and humans. It is an important pathogen in marine mammals and has been isolated from several cetacean species. Brucella ceti expresses several surface antigens that are involved in pathogenesis and are important targets for immunological detection.

One such surface antigen is Omp22, a lipoprotein that is involved in the adhesion and invasion of host cells. Another important surface antigen is M644-93-1, which is involved in the immune response of the host. Additionally, Brucella ceti expresses a variety of other surface antigens, including lipoproteins and proteins, that are important for virulence and pathogenesis.

The identification and characterization of these surface antigens is crucial for the development of effective diagnostic and therapeutic tools for the prevention and treatment of brucellosis. The use of surface antigens as targets for immunological detection has great potential in the development of rapid and accurate diagnostic tests, and in the development of effective vaccines and treatments for this important zoonotic disease.

In conclusion, the study of Brucella ceti surface antigens is an important area of research that has the potential to greatly advance our understanding of the pathogenesis and immunology of this important zoonotic pathogen.

Brucella ceti cDNA and recombinant antigens can be used to detect antibodies to Brucella ceti in serum or other samples. This can be used to diagnose Brucellosis, an infectious disease caused by B. ceti. The antigen can also be used as a vaccine to prevent B. ceti infection. Additionally, the cDNA can be used to study the genetic makeup of the bacterium, which can help researchers understand the pathogenesis of the disease and develop more effective treatments.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.